The Netherlands, August 5 2020 - The Board of Directors of Esperite N.V. (Euronext: ESP), at its meeting of 30 July, 2020, noted the departure of Frédéric Amar from his position as Chief Executive Officer for health reasons. Frédéric Amar maintains his mandate as Director and, as such, will continue to provide Esperite with the benefit of his expertise.
The Board, by unanimous vote of its members, decided to appoint Hugo Brugière as a director and to appoint him as Chief Executive Officer of Esperite. Hugo Brugière is notably Chairman of HBR Investment Group, a company specialising in the acquisition of stakes in distressed companies in need of managerial support in addition to a capital contribution. His most recent investment is Neovacs, a French biotechnology company listed on Euronext Growth in Paris.
Hugo Brugière is one of the investors in the European Small Caps Opportunities Fund, based in Australia (the "Fund"), from which Esperite secured a €35 million financing line on July 28, 2020. It is specified that (i) as a limited partner, Hugo Brugière has no decision-making power within the Fund and (ii) no privileged information that Hugo Brugière may hold in his capacity as Chief Executive Officer and director of Esperite may be transmitted to the Fund, in accordance with the terms of the contract concluded between Esperite and the Fund.
Frédéric Amar: "Esperite was a major project for me. I am pleased to hand over the management of the group to Hugo Brugière, whose energy and foresight make him the manager that Esperite needs for its development. The recent investment agreement that we signed should enable Esperite, under Hugo Brugière's leadership, to envisage an ambitious development plan.
Hugo Brugière said: "After learning of the Fund's investment in Esperite, I was seduced by the potential offered by this company. It was therefore natural for me to accept the directors' offer to join the Board and become Chief Executive Officer. I will take the time to analyse the situation from the inside and then present my action plan. »
This press release contains inside information as referred to in Article 7(1) of Regulation (EU) No 596/2014 (Market Abuse Regulation).
As regards the Member States of the European Economic Area which have transposed the European Directive 2003/71/EC of the European Parliament and of the Council (as amended inter alia by Directive 2010/73/EU to the extent that the said Directive has been transposed in each Member State of the European Economic Area), no action has been taken or will be taken to allow a public offer of the securities referred to in this press release requiring the publication of a prospectus in any Member State.
This press release and the information contained herein do not and will not constitute an offer to subscribe for or sell, or the solicitation of an offer to subscribe for or purchase, securities of Esperite in the United States of America or any other jurisdiction. The securities may not be offered or sold in the United States of America absent registration or an exemption from registration under the U.S. Securities Act of 1933, as amended (the "U.S. Securities Act"), except that the securities of Esperite have not been and will not be registered under the U.S. Securities Act. Esperite does not intend to register securities or make a public offering in the United States of America.